Alterity prepares for end-of-Phase II FDA meeting for ATH434 in MSA
Alterity is preparing for a mid-2026 end-of-Phase II FDA meeting for ATH434 in Multiple System Atrophy. Phase II data showed clinically meaningful and statistically significant effects, with safety comparable to placebo.
Alterity Therapeutics is preparing for an end-of-Phase II meeting with the US Food and Drug Administration targeted for mid-2026 as it advances ATH434 toward a pivotal Phase III trial in Multiple System Atrophy. The company said results from the Phase II program demonstrated that ATH434 was safe and well tolerated, and achieved clinically meaningful and statistically significant effects on a validated clinical scale that measures functional impairment and symptom severity in patients with MSA. These findings were supported by additional clinical and biomarker data.
Results from the Phase II program showed slowing of disease progression across functional measures, mobility metrics and symptoms of orthostatic hypotension. The safety profile remained comparable to placebo, with no drug-related serious or severe adverse events observed. Both active treatment groups also demonstrated stabilisation of orthostatic hypotension symptoms, while placebo patients worsened over the treatment period.
The end-of-phase II meeting represents the final regulatory step before starting a pivotal Phase III trial and is expected to define key elements of the study design, including patient selection, efficacy and safety endpoints, and statistical analyses. ATH434 has received FDA Fast Track designation, enabling more frequent regulatory interactions and supporting an efficient pathway toward late-stage development. Alterity has also received Orphan Drug Designation from the FDA and the European Commission for ATH434 to treat MSA.
The company outlined three priorities for 2026:
- Finalising its regulatory strategy to enable a pivotal Phase III trial
- Deepening engagement across key external stakeholder groups
- Building a scalable platform and team for long-term growth with an emphasis on intellectual property protection
From a clinical perspective, the company said it continues to work closely with leading movement disorder and autonomic neurologists to better understand positioning of ATH434 as a potential disease-modifying therapy. Feedback from physicians consulted during the company’s commercial assessment highlighted the importance of targeting α-synuclein aggregation and acknowledged the relevance of the Phase II data in demonstrating slowed disease progression and stabilisation of orthostatic hypotension.
The company said more than 70% of physicians surveyed indicated they were “extremely likely” or “very likely” to prescribe ATH434 for their MSA patients. Alterity also said discussions with pharmaceutical partners have broadened as interest grows in ATH434’s differentiated clinical profile and substantial commercial opportunity. The company said it anticipates an active year of scientific publications and conference presentations in 2026.